- Sanofi is discontinuing Phase 1 trial of SAR448272.
- SAR448272 is an oral STAT6 degrader.
- The trial was first-in-human.
Sanofi is ending a Phase 1 trial of SAR448272, an oral STAT6 degrader developed with Nurix. The move is a setback for Nurix's pipeline and partnership with Sanofi.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.